<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30</td>
<td>Welcome coffee</td>
</tr>
<tr>
<td>08.45</td>
<td>Introduction, Philippe Métellus</td>
</tr>
<tr>
<td>09.00</td>
<td><strong>Basic and translational research session</strong></td>
</tr>
<tr>
<td></td>
<td><em>Chairs: Manuel Valiente &amp; Kim Margolin</em></td>
</tr>
<tr>
<td>09.00</td>
<td>Preclinical Insights into Brain Metastases of Breast Cancer, Brunilde Gril</td>
</tr>
<tr>
<td>09.30</td>
<td>Genomics of Brain Metastases, Priscilla Brastianos</td>
</tr>
<tr>
<td>10.00</td>
<td>A new pharmacological approach in Brain Metastases, Frits Thorsen &amp; Rolf Bjerkvig</td>
</tr>
<tr>
<td>10.30</td>
<td>Coffee break and visit of the exhibition</td>
</tr>
<tr>
<td></td>
<td><em>Chairs: Francesco Di Meco &amp; Priscilla Brastianos</em></td>
</tr>
<tr>
<td>11.00</td>
<td><strong>Keynote lecture:</strong> Molecular regulation of the critical steps to initiate Brain Metastases, Manuel Valiente</td>
</tr>
<tr>
<td>11.30</td>
<td>Brain Metastases phenotypic heterogeneity, Jacek Jassem &amp; Renata Duchnowska</td>
</tr>
<tr>
<td>12.00</td>
<td>Lunch</td>
</tr>
<tr>
<td>12.30</td>
<td><strong>Symposium</strong></td>
</tr>
<tr>
<td></td>
<td><em>Chairs: Jan Eskandari &amp; Philippe Métellus</em></td>
</tr>
<tr>
<td></td>
<td>CyberKnife radiosurgery for single and multiple cerebral metastases - experiences of the Maria Sklodowska-Curie Memorial Cancer Center, Slawomir Blamek Experience in Brain Metastases treatment with the CyberKnife, Alfredo Conti</td>
</tr>
</tbody>
</table>
13.30 **Parallel academic workshop: expert driven sessions**

- **Team A:** Trial design, end points and inclusion criteria, *Riccardo Soffietti & Manmeet Ahluwalia*
- **Team B:** Combined systemic and local therapies, *Matthias Preusser & Caroline Chung*
- **Team C:** Preventive trials design, *Frank Winkler & Minesh Mehta*

13.30 **Academic workshop feedback and discussion**

- **Team A:** Trial design, end points and inclusion criteria, *Riccardo Soffietti & Manmeet Ahluwalia*
- **Team B:** Combined systemic and local therapies, *Matthias Preusser & Caroline Chung*
- **Team C:** Preventive trials design, *Frank Winkler & Minesh Mehta*

16.00 **Therapeutic session**

*Chairs: Philippe Métellus, Matthias Preusser & Manfred Westphal*

- **16.00** Targeted therapies in Brain Metastases, *Manmeet Ahluwalia*
- **16.30** The value of 5-ALA induced fluorescence for resection of Brain Metastases, *Georg Widhalm*
- **17.00** Preventive strategies for neurocognitive deficits in the management of Brain Metastases, *Minesh Mehta*
- **17.30** **Keynote lecture:** Emerging role of immunotherapies in Brain Metastatic Melanoma, *Kim Margolin*

18.00 **Poster session**

Guided poster walks, cheese & wine

20.00 **Gala dinner**
08.00 Welcome coffee

08.30 TTFields for treatment of primary and metastatic brain tumors – an Update, Zvi Ram

08.45 Selected oral presentations

Chair: Frédéric Dhermain & Zvi Ram

08.45 Pro-metastatic role of LFA-1 in Brain Metastases progression unmarks the potential use of anti-nos and anti-cox therapies, Manuel Sarmiento Soto, United Kingdom

08.55 Identification and characterization of Brain Metastases initiating cells, Anna Sophie Berghoff, Germany

09.05 Flow cytometry assays in CSF improve diagnostic accuracy of leptomeningeal metastases from epithelial tumors and melanoma, Dieta Brandsma, The Netherlands

09.15 Human epidermal growth factor receptor type 2 and hormonal receptors discordances between primary breast cancer and its Brain Metastases, Christophe Joubert, France

09.25 Effect of GAP27 on breast cancer Brain Metastases development: initial results, Valérie De Meulenaere, Belgium

09.35 Development and application of a novel model of human lung-to-Brain Metastases to identify unique metastatic gene signatures, Mohini Singh, Canada

09.45 Molecular detection enables intravital diagnosis in a novel pre-clinical mouse model of spontaneous melanoma Brain Metastases, Hila Schwartz, Israel

09.55 Laboratory parameters have prognostic value in patients with newly diagnosed Brain Metastases: analysis of 1201 cases, Romina Koller, Austria

10.05 T cell response facilitates cerebral metastasis of breast cancer, Dana Mustafa, The Netherlands

10.15 Coffee break and visit of the exhibition
Chairs: Émilie Le Rhun & Philippe Métellus

10.45 RTOG 1119: phase II randomized study of whole brain radiation therapy with concurrent lapatinib in patients with Brain Metastases from HER2+ breast cancer – A collaborative study of NRG and KROG (NCT01622868), Kim In Ah, South Korea

10.55 Stereotactic fractionated radiotherapy of the resection cavity in patients with one to three Brain Metastases, Angelika Bilger, Germany

11.05 Tumor subtype and others prognostic factor for the development of Brain Metastases from breast cancer patients in Indonesia, Rini Andriani, Indonesia

11.15 Surgical resection of Brain Metastases from renal cancer: is it worth it? A French Cancer Center experience, Lauriane Eberst, France

11.25 NRG CC001: phase III trial memantine and whole-brain radiotherapy with or without hippocampal avoidance in patients with Brain Metastases, Minesh P. Mehta, USA

11.35 The dynamics of resolution of metastases-associated edema after surgery vs. SRS, Rachel Grossman, Israel

11.45 Immune response in breast cancer Brain Metastases and their microenvironment, Renata Duchnowska, Poland

11.55 AZD3759, an egfr inhibitor with blood brain barrier (BBB) penetration, for the treatment of EGFRM+ non-small cell lung cancer (NSCLC) with Brain Metastases (BM) and leptomeningeal metastases (LM) – Ongoing phase I study, Sarit Rabbie, United Kingdom

12.05 Fluorescein sodium-guided resection of cerebral metastases – Experience with first 51 patients, Julius Hoehne, Germany

12.15 Treatment of EGFR/ALK-driven non-small cell lung cancer (NSCLC) Brain Metastases: impact of first-line whole brain radiotherapy on outcome, Mark K. Doherty, Canada

12.25 Keynote lecture: Perspectives in Breast Cancer Brain Metastases research approaches, David Cameron

12.55 Awards – Best communication and poster – Conclusions
Chair: Philippe Métellus